Table 50.
Patient demographics and clinical outcomes.
| Early Anti-TNF | Late Anti-TNF | p | |
|---|---|---|---|
| n (%) | 57 (49.6) | 58 (50.4) | |
| Infliximab (%) | 40 (70.2) | 38 (65.5) | 0.59 |
| Adalimumab (%) | 17 (29.8) | 20 (34.5) | |
| Median time to anti-TNF (weeks, IQR) | 38.1 (23.3–91.0) | 414.0 (254.0–561.3) | <0.001 |
| Active or former smoker (%) | 11 (19.3) | 15 (25.9) | 0.76 |
| Pancolitis (%) | 43 (75.4) | 40 (69.0) | 0.44 |
| Endoscopic mayo score at anti-TNF (mean, ±SD) | 2.46 (±0.66) | 1.86 (±0.67) | <0.001 |
| Colectomy (%) | 10 (17.5) | 5 (8.6) | 0.16 |
| UC-related hospitalization | 25 (43.9) | 16 (27.6) | 0.07 |
| Clinical loss of response | 28 (49.1) | 34 (58.6) | 0.31 |